WO2007146039A2 - Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide - Google Patents

Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide Download PDF

Info

Publication number
WO2007146039A2
WO2007146039A2 PCT/US2007/013384 US2007013384W WO2007146039A2 WO 2007146039 A2 WO2007146039 A2 WO 2007146039A2 US 2007013384 W US2007013384 W US 2007013384W WO 2007146039 A2 WO2007146039 A2 WO 2007146039A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
crystalline form
powder
ray diffraction
diffraction pattern
Prior art date
Application number
PCT/US2007/013384
Other languages
English (en)
French (fr)
Other versions
WO2007146039A3 (en
Inventor
Jack Z. Gougoutas
Mary F. Malley
John D. Dimarco
Soojin Kim
Hai-Yun Xiao
Raj Narain Misra
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to EP07795829A priority Critical patent/EP2044066A2/en
Priority to JP2009514368A priority patent/JP2009539846A/ja
Publication of WO2007146039A2 publication Critical patent/WO2007146039A2/en
Publication of WO2007146039A3 publication Critical patent/WO2007146039A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention generally relates to crystalline forms of N-[5-[[[5-(l,l- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline form of N-[5-[[[5-(l,l-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide, as well as a method of using a crystalline form of N-[5-[[[5-(l,l- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide in the treatment of proliferative diseases such as cancer, and of inflammation.
  • N-[5-[[[5-(l,l-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide has the structure of formula I:
  • Compound I Compound I, salts of Compound I, and processes to prepare Compound I and salts are disclosed in U.S Patent 6,515,004 Bl , which is assigned to the present assignee and is incorporated herein by reference in its entirety.
  • U.S. Patents 6,040,321, 6,214,852 Bl, 6,262,096 Bl, 6,392,053 B2, 6,414,156 B2, 6,515,004 Bl, 6,521,759, 6,613,911 B2, 6,639,074 B2, and 6,897,321 B2, which are assigned to the present assignee, are also incorporated herein by reference in their entirety.
  • Compound I is suitable as an inhibitor of protein kinases such as the cyclin dependent kinases (cdks), for example, cdc2 (cdkl), cdk2, cdk3, cdk4, cdk5, cdk ⁇ , cdk7, and cdk8.
  • cdks protein kinases
  • Compound I is expected to be useful in the therapy of proliferative diseases such as cancer, and in the therapy of inflammation, arthritis, Alzheimer's disease, cardiovascular disease, and autoimmune disorders.
  • a form of the active ingredient is sought that has a balance of desired properties such as dissolution rate, solubility, bioavailability, and/or storage stability.
  • desired properties such as dissolution rate, solubility, bioavailability, and/or storage stability.
  • a form of the active ingredient which has the requisite solubility and bioavailability, also has sufficient stability that it does not convert during manufacture or storage of the pharmaceutical composition to a different form, which has different solubility and/or bioavailability.
  • One or more forms of Compound I or salt thereof are desired having properties and stability that allow the preparation of pharmaceutical compositions suitable for the treatment of diseases such as cancer. Further, one or more forms of Compound I or salt thereof are desired that allow the isolation and/or purification of Compound I, for example, during a preparative process.
  • Another aspect of the present invention provides a crystalline form of the hemi-L- tartrate salt of Compound I comprising Form M-2.
  • Another aspect of the present invention provides a crystalline form of the hemi-L- tartrate salt of Compound I comprising Form FA-4.
  • Another aspect of the present invention provides a crystalline form of the dihydrogen chloride salt of Compound I comprising Form H3-1.
  • Another aspect of the present invention provides a crystalline form of the hydrogen bromide salt of Compound I comprising Form H-I.
  • Another aspect of the present invention provides a crystalline form of the hydrogen iodide salt of Compound I comprising Form H-I .
  • Another aspect of the present invention provides a crystalline form of the trifluoroacetate salt of Compound I comprising Form N-I .
  • Another aspect of the present invention provides a crystalline form of the hemi-L- tartrate salt of Compound I comprising Form N-I .
  • Another aspect of the present invention provides a crystalline form of the hemi- fumarate salt of Compound I comprising Form E-I .
  • Another aspect of the present invention provides a crystalline form of the hemi- succinate salt of Compound I comprising Form E-I.
  • Another aspect of the present invention provides a crystalline form of the free base of Compound I comprising Form H-I.
  • Another aspect of the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising one or more of: Form N-3, Form N-I , Form M-2, and/or Form FA-4 of the hemi-L-tartrate salt of Compound I, Form H3-1 of the dihydrogen chloride salt of Compound I, Form H-I of the hydrogen bromide salt of Compound I, Form H-I of the hydrogen iodide salt of Compound I, Form N-I of the trifluoroacetate salt of Compound I, Form E-I of the hemi-fumarate salt of Compound I, Form E-I of the hemi-succinate salt of Compound I, and/or Form H-I of the free base of Compound I; and a pharmaceutically acceptable carrier or diluent.
  • Another aspect of the present invention provides a method for treating a proliferative disease, comprising administering to a mammalian species in need thereof, a therapeutically effect amount of Compound I, wherein Compound I is provided in a crystalline form comprising Form N-3, Form N-I , Form M-2, and/or Form FA-4 of the hemi-L-tartrate salt of Compound I, Form H3-1 of the dihydrogen chloride salt of Compound I, Form H-I of the hydrogen bromide salt of Compound I, Form H-I of the hydrogen iodide salt of Compound I, Form N-I of the trifluoroacetate salt of Compound I, Form E-I of the hemi-fumarate salt of Compound I, Form E-I of the hemi-succinate salt of Compound I, and/or Form H-I of the free base of Compound I.
  • FIG. 7 shows simulated powder x-ray diffraction pattern at room temperature
  • the abscissa is in units of degrees 2 ⁇ , and the ordinate represents the intensity as the number of counts.
  • FIG. 12 shows a differential scanning calorimetry (DSC) thermogram of the N-3 crystalline form of the hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • FIG. 13 shows a thermogravimetric analysis (TGA) thermogram of the N-3 crystalline form of the hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • FIG. 14 shows a differential scanning calorimetry thermogram of the M-2 crystalline form of the hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • FIG. 15 shows a thermogravimetric analysis (TGA) thermogram of the M-2 crystalline form of the hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • TGA thermogravimetric analysis
  • FIG. 16 shows a differential scanning calorimetry thermogram of the H-I crystalline form of N-[5-[[[5-(l,l-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide.
  • FIG. 17 shows a thermogravimetric analysis (TGA) thermogram of the H-I crystalline form of N-[5-[[[5-(l , 1 -dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide.
  • FIG. 18 shows a differential scanning calorimetry thermogram of the N-I crystalline form of hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • TGA thermogravimetric analysis
  • thermogravimetric analysis (TGA) thermogram of the N-I crystalline form of hemi L-tartrate salt of N-[5-[[[5-(l,l-dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide.
  • FIG. 20 shows the centro symmetric solvent site in the triclinic crystal structure of the base.
  • the centrosymmetric solvent site (volume ⁇ 75 A 3 , violet net) in the triclinic crystal structure of the base, from aq. EtOH. Electron density corresponding to an oxygen atom was observed at the center of each site (black circle) but one water obviously does not fill the site, and the minimum (Nl 8 - center) distance of 3.40A is too long for any significant H-bond interaction.
  • a molecule of acetonitrile (disordered end-for-end) may also fit in the site.
  • One (ordered) chloride ion could fit in the site, suggesting the possible crystallization of an isostructural hemi- hydrochloride (i.e. 2 molecules of base + 1 HCl).
  • FIG. 21 shows the H-bonding in the pseudocentrosymmetric crystal structure of the (2: 1 ) L-tartrate salt, form N- 1.
  • FIG. 22 shows the H-bonding in the crystal structure of the (2:1) L-tartrate salt, form N-3.
  • FIG. 23 shows the structure of the hemitartrate (form M-2).
  • the two independent cations of achiral Compound I adopt enantiomeric conformations which H-bond to the homochiral dianion of L-tartaric acid in a pseudo centrosymmetric arrangement.
  • the two independent molecules of methanol are also pseudo centrically H-bonded to the two carboxylate anions.
  • FIGs. 24a-c Modes of conformation and H-bonding in salts of Compound I.
  • polymorphs refer to crystalline forms having the same chemical compositions but different spatial arrangements of the molecules and/or ions forming the crystals.
  • amorphous refers to a solid form of a molecule and/or ions that is not crystalline. An amorphous solid does not display a definitive X-ray diffraction pattern with sharp maxima.
  • the crystal forms provided herein are provided in substantially pure form. In other embodiments, the crystal forms provided herein are provided as mixtures with either other crystal forms or amorphous material. In certain embodiments, the crystal forms are present in such mixtures in an amount as low as the limit of detection. In other embodiments, the crystal forms are present in such mixtures at greater than about 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 75, 85, 90, 95, 96, 97, 98, 99 or 99.5 % by weight.
  • compositions provided herein are comprised of crystal forms that are in substantially pure form. In other embodiments, the compositions provided herein are comprised of crystal forms in mixtures with either other crystal forms or amorphous material. In certain embodiments, the compositions are comprised of crystal forms that are present in such mixtures in an amount as low as the limit of detection. In other embodiments, the compositions are comprised of crystal forms that are present in such mixtures at greater than about 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 75, 85, 90, 95, 96, 97, 98, 99 or 99.5 % by weight.
  • the parameter "molecules/asymmetric unit” refers to the number of molecules of Compound I in the asymmetric unit.
  • unit cell parameter refers to the number of molecules of Compound I in the unit cell.
  • the crystalline form of Compound I When dissolved, the crystalline form of Compound I loses its crystalline structure, and is therefore referred to as a solution of Compound I.
  • One or more of the crystalline forms of Compound I disclosed herein, may be used for the preparation of liquid formulations in which the compound is dissolved or suspended.
  • hemi-L-tartrate salt of Compound I Form H3-1 of the dihydrogen chloride salt of Compound I, Form H-I of the hydrogen bromide salt of Compound I, Form H-I of the hydrogen iodide salt of Compound I, Form N-I of the trifluoroacetate salt of Compound I, Form E-I of the hemi-fumarate salt of Compound I, Form E-I of the hemi-succinate salt of Compound I, and/or Form H-I of the free base of Compound I may be combined with a pharmaceutically acceptable carrier or diluent to provide pharmaceutical compositions of this invention.
  • therapeutically effective amount it is meant an amount that, when administered alone or an amount when administered with an additional therapeutic agent, is effective to prevent, suppress, or ameliorate a disease or condition or the progression of a disease or condition.
  • the present invention provides crystalline forms of Compound I, including salts of Compound I.
  • One aspect of the invention provides an anhydrous, non-solvated crystalline form of a hemi-L-tartrate salt of Compound I and is referred to herein as the "Form N-3" or "N-3 Form” of the hemi-L-tartrate salt of Compound I.
  • the composition this hemi-L- tartrate salt form comprises one molecule of L-tartaric acid for each two molecules of Compound I.
  • the N-3 Form of the hemi-L-tartrate salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 1.
  • the N-3 Form of the hemi-L-tartrate salt of Compound I is characterized by a powder x- ray diffraction pattern substantially in accordance with the observed powder x-ray diffraction pattern shown in Figure 1.
  • the N-3 form of the hemi- L-tartrate salt is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 1 and with the observed powder x-ray diffraction pattern shown in Figure 1.
  • Form N-3 of the hemi-L-tartrate salt of Compound I is characterized by fractional atomic coordinates substantially as listed in Table 1.
  • Table 1 Fractional Atomic Coordinates for Form N-3 of the hemi-L-tartrate salt of
  • the N-3 Form of the hemi-L-tartrate salt of Compound I is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 12.
  • the N- 3 Form of the hemi-L-tartrate salt of Compound I is characterized by a melting temperature in the range of about 243-251 0 C.
  • the N-3 Form of the hemi-L-tartrate salt of Compound I is characterized by a thermogravimetric analysis (TGA) thermogram having no significant weight loss, in one embodiment, having weight loss of approximately -0.14 weight %, upon heating to a temperature of about 150 0 C.
  • TGA thermogravimetric analysis
  • the invention also provides the N-3 Form of the hemi-L-tartrate salt of Compound I that exhibits a TGA thermogram substantially the same as shown in Figure 13.
  • the N-3 Form of the hemi-L-tartrate salt of Compound T is provided in substantially pure form.
  • This N-3 Form of the hemi-L-tartrate salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • N-3 Form of the hemi-L-tartrate salt of Compound I is provided in substantially pure form as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • N-3 Form of the hemi-L-tartrate salt of Compound I is provided with phase homogenicity as indicated by an analysis of the total peak area in the experimentally measured powder x- ray diffraction (PXRD) pattern arising from extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x- ray diffraction
  • One embodiment is a crystalline form having substantially pure phase homogeneity with less than 1% of the total peak area in the experimentally measured PXR-D pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the N-3 Form of the hemi-L-tartrate salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the N-3 Form of the hemi-L-tartrate salt of Compound I.
  • a composition is provided comprising the N-3 Form of the hemi-L-tartrate salt of Compound I in substantially pure form.
  • This Form N-3 of the hemi-L-tartrate salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the N-3 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in the N-3 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in the N-3 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • composition of this hemi-L-tartrate salt form of Compound I comprises one molecule of L-tartaric acid for each two molecules of Compound I and about one molecule of methanol for each molecule of Compound I.
  • compositions of the M-2 Form of the hemi-L-tartrate salt of Compound I which comprise less than one molecule of methanol for each molecule of Compound I.
  • compositions of the M-2 Form of the hemi-L-tartrate salt of Compound I which comprise about 0.5 molecule of methanol for each molecule of Compound I.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 2.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by a powder x- ray diffraction pattern substantially in accordance with the observed powder x-ray diffraction pattern shown in Figure 2.
  • Form M-2 of the hemi- L-tartrate salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern and the observed powder x-ray diffraction pattern shown in Figure 2.
  • Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by fractional atomic coordinates substantially as listed in Table 2.
  • Table 2 Fractional Atomic Coordinates for Form M-2 of the Hemi-L-Tartrate Salt of
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 14.
  • the Form M-2 of the hemi-L- tartrate salt of Compound I may be characterized by an endothermic event in the range of from about 132°C to about 160 0 C, as measured by DSC.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by a thermogravimetric analysis (TGA) thermogram having weight loss of approximately 2.9 weight % upon heating to a temperature of about 162°C.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is characterized by a thermogravimetric analysis (TGA) thermogram having weight loss of approximately 6.1 weight % upon heating to a temperature of about 200°C.
  • TGA thermogravimetric analysis
  • the invention also provides the Form M-2 of the hemi-L-tartrate salt of Compound I that exhibits a TGA thermogram substantially the same as shown in Figure 15.
  • Compound I is provided in substantially pure form.
  • This Form M-2 of the hemi-L- tartrate salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I is provided in substantially pure form has substantially pure phase homogeneity as indicated by an analysis of the total peak area in the experimentally measured powder x- ray diffraction (PXRD) pattern arising from extra peaks that are absent from the simulated PXRD pattern.
  • Form M-2 of the hemi-L-tartrate salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the Form M-2 of the hemi-L-tartrate salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition comprising the M-2 Form of the hemi-L-tartrate salt of Compound I in substantially pure form.
  • a composition is provided consisting essentially of the Form M-2 of the hemi-L-tartrate salt of Compound I.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the Form M-2 of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in the Form M-2 of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in the Form M-2 of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • Another aspect of the invention provides a crystalline form of a hemi-L-tartrate salt of Compound I and is referred to herein as the "Form FA-4" or "FA-4 Form" of the hemi-L-tartrate salt of Compound I.
  • the composition of this hemi-L-tartrate salt form comprises one molecule of L-tartaric acid for each two molecules of Compound I; and about one molecule of formamide for each molecule of Compound 1.
  • compositions of the FA-4 Form of the hemi-L-tartrate salt of Compound I which comprise less than one molecule of formamide for each molecule of Compound I.
  • compositions of Form M-2 which comprise less than one molecule of methanol for each molecule of Compound I.
  • Density (calculated) 1.383 g/cm 3 wherein measurement of said crystalline form is at a temperature of about -50 0 C.
  • the FA-4 Form of the hemi-L-tartrate salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 3.
  • FA-4 Form of the hemi-L-tartrate salt of Compound I is provided in substantially pure form.
  • This FA-4 Form of the hemi-L-tartrate salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the FA-4 Form of the hemi-L-tartrate salt of Compound I is provided in substantially pure form as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the FA-4 Form of the hemi-L-tartrate salt of Compound I is provided in substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the FA-4 Form of the hemi-L-tartrate salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition is provided consisting essentially of the
  • a composition comprising the FA-4 Form of the hemi-L-tartrate salt of Compound I in substantially pure form.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the FA-4 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in the FA-4 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in the FA-4 Form of the hemi-L-tartrate salt of Compound I, based on the total weight of Compound I in the composition.
  • This Form FA-4 of the hemi-L-tartrate salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • composition of this dihydrogen chloride salt form comprises two molecules of hydrogen chloride for each molecule of Compound I and approximately three molecules of water for each molecule of Compound I.
  • the invention includes compositions of the H3-1 Form of the dihydrogen chloride salt of Compound I which comprise less than three molecules of water for each molecule of Compound I.
  • Density (calculated) 1.364 g/cm 3 wherein measurement of said crystalline form is at a temperature of about -33°C.
  • the H3-1 Form of the dihydrogen chloride salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 4.
  • the H3-1 Form of the dihydrogen chloride salt of Compound I is provided in substantially pure form.
  • the H3-1 Form of the dihydrogen chloride salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x- ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x- ray diffraction
  • the H3-1 Form of the dihydrogen chloride salt of Compound I is provided in substantially pure form as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the H3-1 Form of the dihydrogen chloride salt of Compound I is provided in substantially pure form.
  • the H3-1 Form of the dihydrogen chloride salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in another embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the H3-1 Form of the dihydrogen chloride salt of Compound I.
  • a composition comprising the H3-1 Form of the dihydrogen chloride salt of Compound I in substantially pure form.
  • This Form H3-1 of the dihydrogen chloride salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the H3-1 Form of the dihydrogen chloride salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in the H3-1 Form of the dihydrogen chloride salt of Compound I, based on the total weight of Compound I in the composition. In another embodiment, the composition comprises at least 99 weight % of Compound I in the H3-1 Form of the dihydrogen chloride salt of Compound I, based on the total weight of Compound I in the composition.
  • Another aspect of the invention provides a crystalline form of the monohydrate of the Compound I hydrogen bromide salt and is referred to herein as the "Form H-I" or "H- 1 Form" of the hydrogen bromide salt of Compound I.
  • the composition of this hydrogen bromide salt form comprises one molecule of hydrogen bromide for each molecule of Compound I and about one molecule of water for each molecule of Compound I.
  • the invention includes compositions of the H-I Form of the hydrogen bromide salt of Compound I comprising less than one molecule of water for each molecule of Compound I.
  • Form H-I of the hydrogen bromide salt of Compound I is characterized by unit cell parameters approximately equal to the following:
  • Density (calculated) 1.386 g/cm 3 wherein measurement of said crystalline form is at a temperature of about 22°C.
  • the Form H-I of the hydrogen bromide salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 5.
  • the Form H-I of the hydrogen bromide salt of Compound I is provided in substantially pure form as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the Form H-I of the hydrogen bromide salt of Compound I is provided in substantially pure form as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • a crystalline form having substantially pure phase homogeneity with less than 1% of the total peak area in the experimentally measured PXRD pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the Form H-I of the hydrogen bromide salt of Compound I is provided in substantially pure form.
  • the Form H-I of the hydrogen bromide salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form H-I of the hydrogen bromide salt of Compound I.
  • a composition comprising the Form H-I of the hydrogen bromide salt of Compound I in substantially pure form.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in Form H-I of the hydrogen bromide salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in Form H- 1 of the hydrogen bromide salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in Form H-I of the hydrogen bromide salt of Compound I, based on the total weight of Compound I in the composition.
  • the Form H-I of the hydrogen bromide salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • Another aspect of the invention provides a crystalline form of the monohydrate of the hydrogen iodide salt of Compound I and is referred to herein as the "Form H-I" or "H-I Form" of the hydrogen iodide salt of Compound I.
  • the composition of this hydrogen iodide salt form comprises one molecule of hydrogen iodide for each molecule of Compound I and about one molecule of water for each molecule of Compound I.
  • the invention includes compositions of the H-I Form of the hydrogen iodide salt of Compound I which comprise less than one molecule of water for each molecule of Compound I.
  • the invention includes compositions of the H-I Form of the hydrogen iodide salt of Compound I which comprise about 0.75 molecules of water for each molecule of Compound I.
  • the Form H-I of the hydrogen iodide salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 6.
  • the Form H-I of the hydrogen iodide salt of Compound I is provided in substantially pure form.
  • the Form H- 1 of the hydrogen iodide salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, less than 5%, and less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form H-I of the hydrogen iodide salt of Compound I is provided in substantially pure form, as indicated by analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form H-I of the hydrogen iodide salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form H-I of the hydrogen iodide salt of Compound I.
  • a composition comprising the Form H-I of the hydrogen iodide salt of Compound I in substantially pure form.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the Form H-I of the hydrogen iodide salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in the Form H-I of the hydrogen iodide salt of Compound 1, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in the Form H-I of the hydrogen iodide salt of Compound I, based on the total weight of Compound I in the composition.
  • This Form H-I of the hydrogen iodide salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • a crystal form in substantially pure form which has a PXRX) pattern substantially similar to the patterns in Figures 5 and 6, and which contains Compound I as a mixture of the hydrogen bromide salt and the hydrogen iodide salt.
  • the crystal form contains the bromide ion in an amount between 0.1% and 99.9%, in another embodiment between 50.0% and 99.9%, in another embodiment between
  • This crystal form may be described as a solid solution of the hydrogen iodide and hydrogen bromide salts of Compound I.
  • Another aspect of the invention provides an anhydrous, non-solvated crystalline form of the trifluoroacetic acid salt of the Compound I and is referred to herein as the "Form N-I" or "N-I Form” of the trifluoroacetic acid salt of Compound I.
  • the composition of this trifluoroacetic acid salt form comprises one molecule of trifluoroacetic acid for each molecule of Compound I.
  • Form N-I of the trifluoroacetic acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 7.
  • the Form N-I of the trifluoroacetic acid salt of Compound I is provided in substantially pure form.
  • the Form N-I of the trifluoroacetic acid salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form N-I of the trifluoroacetic acid salt of Compound I is provided in substantially pure form as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form N-I of the trifluoroacetic acid salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition is provided consisting essentially of the
  • a composition comprising the Form N-I of the trifluoroacetic acid salt of Compound I in substantially pure form.
  • the composition of this embodiment may comprise at least 90 weight % of Compound 1 in Form N-I of the trifluoroacetic acid salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in Form N- 1 of the trifluoroacetic acid salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in Form N-I of the trifluoroacetic acid salt of Compound I, based on the total weight of Compound I in the composition.
  • This Form N-I of the trifluoroacetic acid salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • composition of this form, Form H-I of Compound I comprises about one molecule of water for each molecule of Compound I.
  • compositions of the H-I Form of Compound I which comprise less than one molecule of water for each molecule of Compound I.
  • compositions of the H-I Form of Compound I which comprise between about 0.3 and 1 molecule of water for each molecule of Compound I.
  • the invention includes compositions of a dehydrated hydrate H-I Form of Compound I which contains essentially no water in the crystal lattice.
  • Form H-I of Compound I is characterized by unit cell parameters approximately equal to the following:
  • the Form H-I of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x- ray diffraction pattern shown in Figure 8.
  • the Form H-I of Compound I is characterized by fractional atomic coordinates substantially as listed in Table 3.
  • Table 3 Fractional Atomic Coordinates for Form H-I of Compound I at Temperature
  • Form H-I of Compound I is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 16.
  • the Form H-I of Compound I is characterized by a thermogravimetric analysis (TGA) thermogram having weight loss in the range of from about 0 to about 2 weight % upon heating to a temperature of about 125°C.
  • TGA thermogravimetric analysis
  • the Form H-I of Compound I is characterized by a TGA having weight loss of approximately 1.6 weight % upon heating to a temperature of about 125°C.
  • the invention also provides the H-I Form of Compound I that exhibits a TGA thermogram substantially the same as shown in Figure 17.
  • the Form H-I of Compound I is provided in substantially pure form.
  • the Form H-I of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • the Form H-I of Compound I is provided in substantially pure form, as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • Form H- 1 of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form H-I of Compound I.
  • a composition comprising the Form H-I of Compound I in substantially pure form.
  • the composition of this embodiment may comprise at least 90 weight % of the Form H-I of Compound I, based on the weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of the Form H-I of Compound I, based on the weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of the Form H-I of Compound I, based on the weight of Compound I in the composition.
  • This Form H-I of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • compositions of this hemi-fumaric acid salt form comprises one molecule of fumaric acid for each two molecules of Compound I and about one molecule of ethanol for each molecule of Compound I.
  • compositions of the E-I Form of the hemi-fumarate salt of Compound I comprising less than one molecule of ethanol for each molecule of Compound I.
  • compositions of the E-I Form of the hemi-fumarate salt of Compound I comprising between about 0.8 and about 1.0 molecule of ethanol for each molecule of Compound I.
  • the Form E- 1 of the hemi-fumaric acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 9.
  • the Form E-I of the hemi-fumaric acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the observed powder x-ray diffraction pattern shown in Figure 9.
  • Form E-I of the hemi-fumaric salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern and the observed powder x-ray diffraction pattern shown in Figure 9.
  • the Form E-I of the hemi-fumaric acid salt of Compound I is provided in substantially pure form.
  • the Form E-I of the hemi-fumaric acid salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form E-I of the hemi-fumaric acid salt of Compound I is provided in substantially pure form, as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • Form E-I of the hemi-fumaric acid salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form E-I of the hemi-fumaric acid salt of Compound I.
  • a composition comprising the Form E-I of the hemi-fumaric acid salt of Compound I in substantially pure form.
  • This Form E-I of the hemi-fumaric acid salt of Compound I in substantially pure form may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in the Form E-I of the hemi-fumaric acid salt of Compound I, based on the total weight Compound I in the composition. In another embodiment, the composition comprises at least 95 weight % in the Form E-I of the hemi-fumaric acid salt of Compound I, based on the total weight Compound I in the composition. In another embodiment, the composition comprises at least 99 weight % of Compound I in the Form E-I of the hemi- fumaric acid salt of Compound I, based on the total weight Compound I in the composition.
  • Another aspect of the invention provides a crystalline form of the hemi-L-tartaric acid salt of Compound I, which is referred to herein as the "Form N-I" or "N-I Form” of the hemi-L-tartaric acid salt of Compound I.
  • the composition of this form comprises one molecule of L-tartaric acid for each two molecules of Compound I.
  • Density (calculated) 1.362 g/cm 3 wherein measurement of said crystalline form is at a temperature of about 22°C.
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 10.
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the observed powder x-ray diffraction pattern shown in Figure 10.
  • Form N-I of the hemi-L-tartaric acid salt of Compound I is characterized by a powder x-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern and the observed powder x-ray diffraction pattern shown in Figure 10.
  • Form N-I of the hemi-L-tartaric acid salt of Compound I is characterized by fractional atomic coordinates substantially as listed in Table 4.
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I is characterized by a differential scanning calorimetry thermogram substantially in accordance with that shown in Figure 18.
  • Compound I is characterized by a thermogravimetric analysis (TGA) thermogram having a smooth baseline until ca. 225°C when a steep weight loss, due to decomposition, is observed.
  • TGA thermogravimetric analysis
  • the invention also provides the N-I Form of the hemi L-tartaric acid salt of Compound I that exhibits a TGA thermogram substantially the same as shown in Figure 19.
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I is provided in substantially pure form.
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form N-I of the hemi-L-tartaric acid salt of Compound I is provided in substantially pure form, as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • Form N-I of the hemi-L-tartaric acid salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form N-I of the hemi-L-tartaric acid salt of Compound I. In a different embodiment, a composition is provided comprising the Form N-I of the hemi-L-tartaric acid salt of
  • compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the composition of this embodiment may comprise at least 90 weight % of Compound I in Form N-I of the hemi- L-tartaric acid salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 95 weight % of Compound I in Form N-I of the hemi-L-tartaric acid salt of Compound I, based on the total weight of Compound I in the composition.
  • the composition comprises at least 99 weight % of Compound I in Form N-I of the hemi-L-tartaric acid salt of Compound I, based on the total weight of Compound I in the composition.
  • composition of this hemi-succinate salt form comprises one molecule of succinic acid for each two molecules of Compound I and about one molecule of ethanol for each molecule of Compound I.
  • compositions comprising less than one molecule of ethanol for each molecule of Compound I.
  • the Form E-I of the hemi-succinate salt of Compound I is characterized by a powder X-ray diffraction pattern substantially in accordance with the simulated powder x-ray diffraction pattern shown in Figure 11.
  • the Form E-I of the hemi-succinate salt of Compound I is provided in substantially pure form.
  • the Form E- 1 of the hemi-succinate salt of Compound I has substantially pure phase homogeneity as indicated by less than 10%, in one embodiment less than 5%, and in another embodiment less than 2% of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • the Form E-I of the hemi-succinate salt of Compound I is provided in substantially pure form, as indicated by an analysis of the total peak area in the experimentally measured powder x-ray diffraction (PXRD) pattern arising from the extra peaks that are absent from the simulated PXRD pattern.
  • PXRD powder x-ray diffraction
  • Form E-I of the hemi-succinate salt of Compound I may be provided in substantially pure form, wherein substantially pure is greater than 90 weight % pure, in one embodiment greater than 95 weight % pure, and in another embodiment greater than 99 weight % pure.
  • a composition consisting essentially of the Form E-I of the hemi-succinate salt of Compound I.
  • a composition comprising the Form E-I of the hemi-succinate salt of Compound I in substantially pure form.
  • This Form E-I of the hemi-succinate salt of Compound I may be employed in pharmaceutical compositions which may optionally include one or more other components selected, for example, from excipients and carriers; and optionally, one or more other active pharmaceutical ingredients having active chemical entities of different molecular structures.
  • the invention provides a crystal form in substantially pure form which has a PXRD pattern substantially similar to the patterns in Figures 9 and 11, and which contains Compound I as a mixture of the fumarate salt and the succinate salt, and which contains about one molecule of ethanol per molecule of Compound I.
  • the crystal form contains the fumarate ion in an amount between 0.1% and 99.9%, in another embodiment between 50.1%, 60%, 70%, 80%, 90%, 95%, 97%, 98% or 99%, and 99.9%, of the total quantity of anions in the crystal lattice.
  • This crystal form may be described as a solid solution of the fumarate and succinate salts of Compound I.
  • the composition of this embodiment may comprise at least 90 weight % of
  • the composition comprises at least 95 weight % of Compound I in Form E-I of the hemi-succinate salt of Compound I, based on the total weight of Compound I in the composition. In another embodiment, the composition comprises at least 99 weight % of Compound I in Form E-I of the hemi-succinate salt of Compound I, based on the total weight of Compound I in the composition.
  • Compound I is an inhibitor of protein kinases such as the cyclin dependent kinases (cdks), for example, cdc2 (cdkl), cdk2, cdk3, cdk4, cdk5, cdk ⁇ , cdk7 and cdk8.
  • cdks protein kinases
  • Compound I is expected to be useful in the therapy of proliferative diseases such as cancer, and of inflammation, arthritis, Alzheimer's disease, and cardiovascular disease. More specifically, Compound I is useful in the treatment of a variety of cancers, including (but not limited to) the following:
  • -carcinoma including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin; -hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia (ALL), B-cell lymphoma, Burkett's lymphoma, Hodgkin's disease, Non- Hodgkin's lymphoma (NHL) including mantle cell lymphoma (MCL), and cutaneous T- cell lymphoma (CTCL);
  • ALL acute lymphocytic leukemia
  • B-cell lymphoma Burkett's lymphoma
  • NHL Non- Hodgkin's lymphoma
  • MCL mantle cell lymphoma
  • CCL cutaneous T- cell lymphoma
  • AML acute myelogenous leukemia
  • CML chronic myelogenous leukemia
  • PML promyelocytic leukemia
  • MDS myelodysplasia syndrome
  • MM multiple myeloma
  • tumors including melanoma, seminoma, teratocarcinoma, osteosarcoma, neuroblastoma, and glioma.
  • Compound I provided in one or more of the crystalline forms disclosed herein may be useful in the treatment of breast, lung, and/or colorectal cancers.
  • Compound I is provided as a hemi-L- tartrate salt in Form N-3.
  • inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., neurofibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, angiogenesis, and endotoxic shock.
  • Compound I may also be useful in the treatment of Alzheimer's disease, as suggested by the finding that cdk5 is involved in the phosphorylation of tau protein (J. Biochem, 117, 741-749 (1995)).
  • Compound I may also act as an inhibitor of other protein kinases, e.g., protein kinase C, her2, rafl, MEKl, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, AbI, VEGF, and lck, and thus be effective in the treatment of diseases associated with other protein kinases.
  • protein kinase C her2, rafl, MEKl
  • MAP kinase EGF receptor
  • PDGF receptor PDGF receptor
  • IGF receptor PI3 kinase
  • PI3 kinase weel kinase
  • Src AbI
  • VEGF vascular endothelial growth factor
  • lck protein kinase C
  • other protein kinases e.g., protein kinase C, her2, rafl, MEK
  • Compound I may also induce or inhibit apoptosis, a physiological cell death process critical for normal development and homeostasis. Alterations of apoptotic pathways contribute to the pathogenesis of a variety of human diseases.
  • Compound I as a modulator of apoptosis, may be useful in the treatment of a variety of human diseases with aberrations in apoptosis including cancer (including, but not limited to, follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis), viral infections (including, but not limited to, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), autoimmune diseases (including, but not limited to, systemic lupus, erythematosus, immune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel
  • crystal forms provided herein possess improved chemical and physical properties, such as purity profile, stability, solubility, dissolution rate and/or hygroscopicity profile, may be formulated more easily and/or may be manufactured more easily.
  • the invention also provides pharmaceutical compositions which comprise Compound I, wherein Compound I is in one or more of the crystalline forms disclosed herein, and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of the present invention may further comprise one or more pharmaceutically acceptable additional ingredient(s) such as alum, stabilizers, antimicrobial agents, buffers, coloring agents, flavoring agents, and the like.
  • Compound I daily dosages for human administration of Compound I will normally be determined by the prescribing physician with the dosages generally varying according to the age, weight, route of administration, and response of the individual patient, as well as the severity of the patient's symptoms.
  • Compound I may be administered to humans in an amount from about 0.001 mg/kg of body weight to about 100 mg/kg of body weight per day, in one embodiment, from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight per day, and in another embodiment, from about 0.1 mg/kg of body weight to about 20 mg/kg of body weight per day.
  • the solid form of a pharmaceutically active material is important in the preparation of a solid dosage form, such as tablets or capsules as the manufacturing, stability, and/or the performance of the pharmaceutically active material can be dependent upon the solid form.
  • a crystalline form provides pharmaceutically active material with uniform properties, such as solubility, density, dissolution rate, and stability.
  • Compound I provided as a hemi-L-tartrate salt in Form N-3 has properties suitable for the manufacture of tablets or capsules, for providing a stable oral dosage form, and/or for delivery of Compound I to a patient in need thereof.
  • Crystalline forms may be prepared by a variety of methods, including for example, crystallization or recrystallization from a suitable solvent, sublimation, growth from a melt, solid state transformation from another phase, crystallization from a supercritical fluid, and jet spraying.
  • Techniques for crystallization or recrystallization of crystalline forms from a solvent mixture include, for example, evaporation of the solvent, decreasing the temperature of the solvent mixture, crystal seeding a supersaturated solvent mixture of the molecule and/or salt, freeze drying the solvent mixture, and addition of antisolvents (countersolvents) to the solvent mixture.
  • High throughput crystallization techniques may be employed to prepare crystalline forms including polymorphs.
  • Crystals of drugs including polymorphs, methods of preparation, and characterization of drug crystals are discussed in Solid-State Chemistry of Drugs, S. R. Byrn, R.R. Pfeiffer, and J.G. Stowell, 2 nd Edition, SSCI, West Lafayette, Indiana (1999).
  • solvent for crystallization techniques that employ solvent, the choice of solvent or solvents is typically dependent upon one or more factors, such as solubility of the compound, crystallization technique, and vapor pressure of the solvent.
  • Combinations of solvents may be employed, for example, the compound may be solubilized into a first solvent to afford a solution, followed by the addition of an antisolvent to decrease the solubility of the compound in the solution and to afford the formation of crystals.
  • An antisolvent is a solvent in which the compound has low solubility.
  • a compound is suspended and/or stirred in a suitable solvent to afford a slurry, which may be heated to promote dissolution.
  • a suitable solvent to afford a slurry, which may be heated to promote dissolution.
  • slurry means a saturated solution of the compound, which may also contain an additional amount of the compound to afford a heterogeneous mixture of the compound and a solvent at a given temperature.
  • Seed crystals may be added to any crystallization mixture to promote crystallization. Seeding may be employed to control growth of a particular polymorph or to control the particle size distribution of the crystalline product. Accordingly, calculation of the amount of seeds needed depends on the size of the seed available and the desired size of an average product particle as described, for example, in "Programmed Cooling of Batch Crystallizers," J.W. Mullin and J. Nyvlt, Chemical Engineering Science, 1971,26, 369-377. In general, seeds of small size are needed to control effectively the growth of crystals in the batch. Seed of small size may be generated by sieving, milling, or micronizing of large crystals, or by micro-crystallization of solutions.
  • a cooled crystallization mixture may be filtered under vacuum, and the isolated solids may be washed with a suitable solvent, such as cold recrystallization solvent, and dried under a nitrogen purge to afford the desired crystalline form.
  • the isolated solids may be analyzed by a suitable spectroscopic or analytical technique, such as solid state nuclear magnetic resonance, differential scanning calorimetry, powder x-ray diffraction, or the like, to assure formation of the preferred crystalline form of the product.
  • the resulting crystalline form may be produced in an amount of greater than about 70 weight % isolated yield, in one embodiment, greater than 90 weight % isolated yield, based on the weight of the compound originally employed in the crystallization procedure.
  • the product may be comilled or passed through a mesh screen to delump the product, if necessary.
  • Crystalline forms may be prepared directly from the reaction medium of the final process for preparing Compound I. This may be achieved, for example, by employing in the final process step a solvent or a mixture of solvents from which Compound I may be crystallized. Alternatively, crystalline forms may be obtained by distillation or solvent addition techniques.
  • Suitable solvents for this purpose include, for example, the aforementioned nonpolar solvents and polar solvents, including protic polar solvents such as alcohols, and aprotic polar solvents such as ketones.
  • the presence of more than one crystalline form and/or polymorph in a sample may be determined by techniques such as powder x-ray diffraction (PXRD) or solid state nuclear magnetic resonance spectroscopy.
  • PXRD powder x-ray diffraction
  • the simulated PXRD may be calculated from single crystal x-ray data, see Smith, D.K., "A FOR TRAN Program for Calculating X-Ray Powder Diffraction Patterns, " Lawrence Radiation Laboratory, Livermore, California, UCRL-7196 (April 1963).
  • Crystalline forms of Compound I according to the invention may be characterized using various techniques, the operation of which are well known to those of ordinary skill in the art.
  • the crystalline forms of Compound I may be characterized and distinguished using single crystal x-ray diffraction performed under standardized operating conditions and temperatures, which is based on unit cell measurements of a single crystal of the form at a fixed analytical temperature.
  • the approximate unit cell dimensions in Angstroms (A), as well as the crystalline cell volume, space group, molecules per cell, and crystal density may be measured, for example at a sample temperature of 25°C.
  • a detailed description of unit cells is provided in Stout & Jensen, X-Ray Structure Determination: A Practical Guide, Macmillan Co., New York (1968), Chapter 3, which is herein incorporated by reference.
  • the unique arrangement of atoms in spatial relation within the crystalline lattice may be characterized according to the observed fractional atomic coordinates.
  • Another means of characterizing the crystalline structure is by powder x-ray diffraction analysis in which the diffraction profile is compared to a simulated profile representing pure powder material, preferably both run at the same analytical temperature, and measurements for the subject form characterized as a series of 2 ⁇ values (usually four or more).
  • Other means of characterizing the form may be used, such as solid state nuclear magnetic resonance (NMR), differential scanning calorimetry, thermography, and gross examination of the crystalline or amorphous morphology. These parameters may also be used in combination to characterize the subject form.
  • NMR solid state nuclear magnetic resonance
  • thermography thermography
  • the structures were solved by direct methods and refined on the basis of observed reflections using either the SDP software package (SDP Structure Determination Package, Enraf-Nonius, Bohemia, NY) with minor local modifications or the crystallographic package, maXus (maXus Solution and Refinement Software Suite: S. Mackay, CJ. Gilmore, C. Edwards, M. Tremayne, N. Stewart, and K. Shankland).
  • SDP software package SDP Structure Determination Package, Enraf-Nonius, Bohemia, NY
  • maXus crystallographic package
  • the derived atomic parameters were refined through full matrix least-squares.
  • the function minimized in the refinements was Iw(IFoI - IFcI) 2 - R is defined as ⁇
  • while R w [ ⁇ w(
  • X-ray powder diffraction data were obtained using a Bruker C2 GADDS.
  • the radiation was Cu Ka (40 KV, 50mA).
  • the sample-detector distance was 15 cm.
  • Powder samples were placed in sealed glass capillaries of lmm or less in diameter; the capillary was rotated during data collection. Data were collected for 3 ⁇ 2 ⁇ 35° with a sample exposure time of at least 2000 seconds.
  • the resulting two-dimensional diffraction arcs were integrated to create a traditional 1 -dimensional PXRD pattern with a step size of 0.02 degrees 2 ⁇ in the range of 3 to 35 degrees 20.
  • DSC Differential scanning calorimetry
  • TGA Thermal gravimetric analysis
  • the dihydrochloride trihydrate salt of Compound I was crystallized in Form H3-1 from methyl ethyl ketone/methanol/ethanol/aqueous hydrochloric acid to provide colorless intergrown plates: mp 83 (crack), 88-100 (birefringent changes), -135-235 (recryst.) 0 C.
  • Example 6 Form H-I of the Hydrogen Bromide Salt of Compound I
  • Example 10 Form E-I of the Hemi-Fumarate Salt of Compound I The hemi-fumarate salt of Compound I was crystallized in Form E-I from 95% ethanol to provide colorless hexagonal plates: mp ⁇ 142 (crack), 160 (opaque), 185 (needles develop), 208-218 0 C.
  • Example 11 Form N-I of the Hemi-L-Tartrate Salt of Compound I
  • the hemi-L-tartrate salt of Compound I was crystallized in Form N-I from 1 :1 aqueous acetone: mp 240-245 (dec) 0 C.
  • Form N-I of the hemi-L-tartrate salt of Compound I converts to Form N-3. Conversion was observed when a 1 : 1 mixture of 1 :1 Nl :N3 was slurried in 1 :1 acetone: water at room temperature for six days, or at 55 0 C for 20 h.
  • Form N-I can be converted to N-3 by the following procedure.
  • a reaction vessel equipped with mechanical stirrer, thermometer and condenser a mixture of dried Compound I (free base) and 0.55 equivalent of L-tartaric acid or Compound I (tartrate salt) in 1:1 water acetone (6.4 mL/g of free base) is heated to gentle reflux 64-67 0 C) until a solution is obtained. More 1 :1 acetone-water is optionally added. The solution is polish filtered into a reaction vessel and re-heated to 53-56 0 C.
  • Seeds of N-3 form are added to induce crystallization of the right crystalline form, and after the slurry developed, a slow addition of acetone (three times the volume of acetone- water used) is performed.
  • the slurry of Compound I which is then stirred at 53-56 0 C for 3 h and then allowed to cool at room temperature.
  • the solid is collected by filtration and dried in a vacuum oven at room temperature, then at 55-60 0 C to constant weight to give Compound I in approximately 92-95% yield from the free base or approximately 93-98% from the salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
PCT/US2007/013384 2006-06-06 2007-06-06 Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide WO2007146039A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07795829A EP2044066A2 (en) 2006-06-06 2007-06-06 Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
JP2009514368A JP2009539846A (ja) 2006-06-06 2007-06-06 Ｎ−［５−［［［５−（１，１−ジメチルエチル）−２−オキサゾリル］メチル］チオ］−２−チアゾリル］−４−ピペリジンカルボキサミドの結晶形

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81148206P 2006-06-06 2006-06-06
US60/811,482 2006-06-06

Publications (2)

Publication Number Publication Date
WO2007146039A2 true WO2007146039A2 (en) 2007-12-21
WO2007146039A3 WO2007146039A3 (en) 2008-07-17

Family

ID=38668926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013384 WO2007146039A2 (en) 2006-06-06 2007-06-06 Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide

Country Status (3)

Country Link
EP (1) EP2044066A2 (ja)
JP (1) JP2009539846A (ja)
WO (1) WO2007146039A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036954A1 (en) * 2006-09-21 2008-03-27 Sunesis Pharmaceuticals, Inc. Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
KR20160028058A (ko) * 2014-09-02 2016-03-11 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080813A2 (en) * 2000-04-27 2001-11-01 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2002010162A1 (en) * 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6521759B2 (en) * 1999-12-15 2003-02-18 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6639074B2 (en) * 1999-12-15 2003-10-28 Bristol Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808126A (pt) * 1997-02-27 2000-03-08 Pfizer Quinoxalinodionas
GB9711127D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
JP2003506433A (ja) * 1999-08-10 2003-02-18 ロンザ ア−ゲ− ジシアネートカルコンおよびその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6521759B2 (en) * 1999-12-15 2003-02-18 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6639074B2 (en) * 1999-12-15 2003-10-28 Bristol Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
WO2001080813A2 (en) * 2000-04-27 2001-11-01 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2002010162A1 (en) * 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRITAIN ET AL: "Polymorphism in Pharmaceutical Solids passage" POLYMORPHISM IN PHARMACEUTICAL SOLIDS, 1999, pages 235-238, XP002278123 *
GOULD P L: "SALT SELECTION FOR BASIC DRUGS" INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 33, no. 1/3, 1986, pages 201-217, XP002074725 ISSN: 0378-5173 *
HALEBLIAN J ET AL: "PHARMACEUTICAL APPLICATIONS OF POLYMORPHISM" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 58, no. 8, August 1969 (1969-08), pages 911-929, XP002020518 ISSN: 0022-3549 *
MISRA RAJ N ET AL: "N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]m ethyl]thio]-2-thi azolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, no. 7, 25 March 2004 (2004-03-25), pages 1719-1728, XP002302339 ISSN: 0022-2623 *
MORISSETTE SHERRY L ET AL: "HIGH-THROUGHPUT CRYSTALLIZATION: POLYMORPHS, SALTS, CO-CRYSTALS AND SOLCATES OF PHARMACEUTICAL SOLIDS" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 56, no. 3, 2004, pages 275-300, XP009072233 ISSN: 0169-409X *
TONG W-Q ET AL: "IN SITU SALT SCREENING-A USEFUL TECHNIQUE FOR DISCOVERY SUPPORT AND PREFORMULATION STUDIES" PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 3, no. 2, May 1998 (1998-05), pages 215-223, XP001203865 ISSN: 1083-7450 *
YU L ET AL: "PHYSICAL CHARACTERIZATION OF POLYMORPHIC DRUGS: AN INTEGRATED CHARACTERIZATION STRATEGY" PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY, ELSEVIER TRENDS JOURNALS, CAMBRIDGE,, GB, vol. 1, no. 3, June 1998 (1998-06), pages 118-127, XP000949322 ISSN: 1461-5347 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036954A1 (en) * 2006-09-21 2008-03-27 Sunesis Pharmaceuticals, Inc. Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
KR20160028058A (ko) * 2014-09-02 2016-03-11 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도
KR101643280B1 (ko) 2014-09-02 2016-07-28 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도

Also Published As

Publication number Publication date
JP2009539846A (ja) 2009-11-19
EP2044066A2 (en) 2009-04-08
WO2007146039A3 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
US20070105867A1 (en) Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
KR101470715B1 (ko) 다사티닙 다결정체 및 그의 제조방법과 약물 조성물
SG185594A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
TW201638090A (zh) 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法
WO2020244612A1 (zh) Cdk9抑制剂的多晶型物及其制法和用途
EP2044066A2 (en) Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9598413B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
TWI762825B (zh) 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法
US9593116B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US9464086B2 (en) Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
JP5856971B2 (ja) 結晶性ｃｄｃ７阻害剤塩
JP2021533111A (ja) Ｌｔａ４ｈ阻害剤の結晶形態
KR20200140821A (ko) 아베마시클립의 고체-상태 형태, 그의 용도 및 제조
TWI846516B (zh) Cdk9抑制劑的多晶型物及其製法和用途
TWI809330B (zh) Cdk9抑制劑的多晶型物及其製法和用途
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
WO2009158446A2 (en) Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
WO2009120841A1 (en) Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
EA043251B1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
WO2008157211A1 (en) Crystalline forms of (3aalpha,4beta,5alpha,7beta,7aalpha)-4-(octahydro-5-ethylsulfonamido-4,7-dimethyl-1,3-dioxo-4,-7-ep0xy-2h-isoind0l-2-yl)-

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795829

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009514368

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2007795829

Country of ref document: EP